Most of modern medicine is built to treat people once they are already sick. Everlab is betting that the bigger opportunity, clinically and commercially, is catching the problem before it starts, and it has just raised $65 million AUD to prove the point on the global stage.

The Melbourne healthtech has closed an oversubscribed $65M Series A led by Airtree Ventures, with participation from global investors including Plural and returning backers Left Lane Capital and b2venture. The round also drew a notable group of angels, among them Australian Test captain Pat Cummins. 

The thesis is that today's system leaves patients to stitch together their own care. Records sit in isolation with legacy providers, telehealth appointments come and go with no continuity, and wearables generate data without clinical follow-through. Everlab's app pulls diagnostics, doctors, specialists, prescriptions and continuous AI-assisted care into one place, giving members a longitudinal view of their health. 

The platform integrates with 1,850 health provider locations and 180 active clinicians, connects to 30 wearable devices, and processes more than 200,000 health reports a month.

"The existing system is fragmented, handing patients between providers and hoping the information follows," said Marc Hermann, co-founder and CEO of Everlab. "We built Everlab to hold the full picture, surface health blind spots and coordinate what needs to happen next—from targeted screenings to personalised health plans—helping more people live longer, healthier lives."

Everlab has completed 40,000 consultations, supporting 20,000 patients, and processed more than 21 million biomarker test results.

More than 25% of members have had findings flagged that had not been identified through the existing healthcare system.

That record has opened a second front for the business — corporate employers. Everlab now counts Boston Consulting Group, BHP and Bain & Company among its corporate partners, and Hermann says the nature of those conversations has changed. Where wellbeing programs are typically judged on sign-ups, Everlab has pitched something harder to measure and harder to ignore. "We're interested in measurable health outcomes and the behaviours that drive them," Hermann told Overnight Success. "More and more, we're seeing prevention move from being viewed as a wellbeing initiative to being viewed as a performance, productivity and risk-management initiative."

For Everlab's investors, the appeal is a model that has been hard for others to crack. "Every company that has tried to own the patient journey has ended up either selling doctor time by the minute or reselling lab tests with thin margins. Everlab is building the layer above both: the system that interprets and coordinates your health data over time rather than capturing a single transaction. The fact that they've already proven their model operationally in Australia, at scale, is what convinced me this is the version that genuinely works," said Carina Namih, Partner at Plural.

Airtree, which led the round, frames the bet in blunter terms. "The more time we spent with the Everlab team, the more convinced we became that they're building a generational health business. With a world-class product and growing at a pace we rarely see, they're already the leader in Australia and we're backing them to do the same globally," said John Henderson, Partner at Airtree.

What perhaps has been most interesting to watch lately at Everlab is their evolving approach to customer experience. They’ve recently been hiring for the "Dreamweaver" role, inspired by the hospitality book Unreasonable Hospitality, but Hermann is quick to play down the title. 

"We've been slower to hire into the role than most," he said, explaining that the company would rather wait for the right person than fill the seat for its own sake. The point, he argues, is the philosophy rather than the job description: "It's about finding people who genuinely care about helping others and understand that small moments can have an outsized impact on someone's experience." He sees it as foundational to the whole model. 

"Better health outcomes only happen if people stay engaged, and people stay engaged when the experience earns their trust"

His one piece of advice for other founders is that "you can't bolt on these moments later. It has to be embedded in the culture from the beginning." 

With the new capital, Everlab is moving into the $10 trillion global consumer healthcare market, starting with the United Kingdom, and will direct the funding into its clinical and technology infrastructure as it scales the rollout. Hermann, for his part, is keen to temper the moment. "We've made a lot of progress, but I still think we're early. There's a lot more to build," he said.